BRETHINE (terbutaline sulfate) by ANI Pharmaceuticals is clinical pharmacology in vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. First approved in 1976.
Drug data last refreshed 14h ago · AI intelligence enriched 2d ago
Brethine (terbutaline sulfate) is an oral beta-2 adrenergic agonist bronchodilator approved in 1976 for relief of bronchospasm in chronic obstructive pulmonary disease. It works by stimulating beta-2 receptors on bronchial smooth muscle, increasing intracellular cAMP and producing airway relaxation with measurable improvement in pulmonary function within 60-120 minutes. The drug maintains clinical effect for 4-8 hours and demonstrates sustained efficacy comparable to ephedrine over extended treatment periods.
Brethine faces significant generic competition (competitive pressure score: 30/100) with no linked job openings, indicating a mature legacy product with limited growth opportunities and minimal commercial infrastructure.
CLINICAL PHARMACOLOGY In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that…
Worked on BRETHINE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBrethine represents a legacy maintenance product with zero open positions and minimal career growth potential; roles would focus on regulatory compliance, generic defense, and cost management rather than innovation or expansion. Working on this product offers stability in a mature franchise but limited visibility, advancement opportunities, or skill development relevant to emerging therapeutic areas.